Skip to main content

Advertisement

Table 2 Drug-related toxicity per patient for colorectal cancer patients treated with FOLFIRI® and bevacizumab in first-line treatment (n = 62)

From: FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

  NCI-CTCAE* Grade 1–2 NCI-CTCAE Grade 3–4
  N (%) N (%)
Neutropenia 11 (17.7) 10 (16.1)
Febrile neutropenia 0 0
Anemia 4 (6.5) 0
Thrombocytopenia 1 (1.6) 0
Nausea 20 (32.3) 1 (1.6)
Vomiting 6 (9.7) 0
Diarrhea 19 (30.6) 7 (11.3)
Stomatitis/mucositis 16 (25.8) 2 (3.2)
Neurosensory 1 (1.6) 1 (1.6)
Asthenia 3 (4.8) 4 (6.4)
Gastrointestinal perforation 0 0
Hypertension 1 (1.6) 0
Venous thromboembolism 3 (4.8) 0
Proteinuria 8 (12.9) 0
Bleeding 7 (11.3) 0
Alopecia 10 (16.1) 0
  1. *NCI-CTCAE - National Cancer Institute Common Terminology Criteria for Adverse Events v3.0.